Parallax Volatility Advisers
AKCA

Parallax Volatility Advisers’s Akcea Therapeutics Inc AKCA Stock Holding History

Parallax Volatility Advisers’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-25,000
Closed -$876K – 4343
2018
Q3 		$876K Buy
+25,000
New +$756K ﹤0.01% 1308

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.5% 1-Year Est. Return

Parallax Volatility Advisers's AKCA Position: Q2 2019 in Review

Parallax Volatility Advisers sold out of Akcea Therapeutics Inc (AKCA) in Q2 2019, closing a stake of 2,646 shares — an estimated $75K sold.

Parallax Volatility Advisers first reported a position in AKCA in Q4 2017 and held it in 5 quarters. The position peaked at $934K in Q4 2018. 68 funds tracked by Wall St. Rank hold AKCA as of Q2 2019.

  • Parallax Volatility Advisers reported no remaining Akcea Therapeutics Inc position as of Q2 2019 after selling out during the quarter.
  • Parallax Volatility Advisers sold 2,646 Akcea Therapeutics Inc shares in Q2 2019, an estimated $75K.
  • Parallax Volatility Advisers first reported a position in Akcea Therapeutics Inc in Q4 2017 and held it in 5 quarters.
  • Parallax Volatility Advisers's Akcea Therapeutics Inc position peaked at $934K in Q4 2018.
  • 68 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q2 2019.

Based on Parallax Volatility Advisers's 13F filing for Q2 2019, filed 14 Aug 2019.